Skip to main content
. 2020 May 28;20(2):1630–1636. doi: 10.3892/etm.2020.8809

Figure 1.

Figure 1

Liq treatment inhibits the viability and promotes the sensitization of MDA-MB-231 cells to DOX treatment. (A) MDA-MB-231 cells were treated with (A) Liq (0-160 µg/ml), (B) DOX (0-4 ng/ml) or a combination of DOX (0-4 ng/ml) and Liq (40 µg/ml), and (C) DOX (1 ng/ml), Liq (40 µg/ml) or a combination of DOX (1 ng/ml) and Liq (40 µg/ml) for 48 h. Subsequently, cell viability was determined using the Cell Counting Kit-8 assay in triplicate. (D) MDA-MB-231 cells were treated with DOX (1 ng/ml), Liq (40 µg/ml) or a combination of DOX (1 ng/ml) and Liq (40 µg/ml). Subsequently, cell proliferation was assessed using a clone formation assay. Magnification, x100. *P<0.05 vs. the negative control group. #P<0.05 vs. the DOX-treated group. Liq, liquiritigenin; DOX, doxorubicin; OD, optical density; Ctrl, control.